UNSPSC 51162413: Ephedrine/guaifenesin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE516. This VA Drug Class (RE516) classifies this compound as belonging to the group DECONGESTANT/EXPECTORANT.

UNSPSC 51162413 Ephedrine/guaifenesin is a Commodity code nominally covering a single active pharmaceutical ingredient combination, but recent state and local procurement activity shows no direct solicitation for this product. The two recent opportunities tagged to this code actually address broader pharmaceutical procurement: Seminole County, Florida is seeking naloxone and drug deactivation systems through an IFB, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is establishing contracts for generic multi-source pharmaceuticals and OTC products across member jurisdictions. Neither opportunity targets ephedrine/guaifenesin specifically, indicating a mismatch between the code assignment and the work actually being solicited.

The geographic activity centers on Florida and Minnesota, with MMCAP's RFP extending to participating states including Oregon. Issuing bodies include county health departments (Seminole County) and state cooperative purchasing platforms (MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement). The Seminole County IFB (IFB60459723LAS) closes July 26, 2023, and requires quarterly delivery of 1,900 units of naloxone and 800 drug deactivation systems annually with a two-year initial term and one-year renewal option. The MMCAP RFP (S1070000015802) accepts proposals through March 26, 2026, with contracts effective July 1, 2026, and demands manufacturers maintain relationships with AmerisourceBergen, Cardinal Health, and Morris & Dickson, comply with cGMP and the Drug Supply Chain Security Act, and accept a 3 percent administrative fee. Code 51162413 shows little relevant recent activity under its nominal scope.